Singh added that results from the ongoing FOCUS studya long-term ophthalmic endpoint trial evaluating semaglutide versus placebo in patients with type 2 diabeteswill be critical in clarifying the long-term retinal safety profile of GLP-1 therapies
Multiple clinical studies have confirmed semaglutides effectiveness, showing an average reduction of approximately 10% or greater in total body weight for individuals receiving treatment over several months to a year
Aerobic activity (3060 min) on most days of the week can lead to a small amount of weight and fat loss, improvement in cardiometabolic parameters, maintenance of fat-free mass during weight loss and weight maintenance after weight loss [298]
So its very much patient-dependent
When the researchers combined these related measures, they found an overall moderate improvement in binge-eating-related symptoms
Tirzepatide (Mounjaro / Zepbound) a weekly injectable that acts on both GLP-1 and GIP receptors, offering added benefits for glucose and fat metabolism